A cost effectiveness analysis of solifenacin compared with extended-release tolterodine for the treatment of overactive bladder

被引：0

作者：

Kang, H. H. ^{[1
]}

Bae, J. Y. ^{[1
]}

Park, S. Y. ^{[1
]}

Sohn, H. S. ^{[1
]}

机构：

[1] Sock Myung Womens Univ, Seoul, South Korea

来源：

VALUE IN HEALTH | 2007年 / 10卷 / 06期

关键词：

D O I：

10.1016/S1098-3015(10)65151-0

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A319 / A319

页数：1

共 50 条

[31] The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
Ulahannan, Danny
Wagg, Adrian
CLINICAL INTERVENTIONS IN AGING, 2009, 4 : 191 - 196
[32] Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients
Takei, M
Homma, Y
INTERNATIONAL JOURNAL OF UROLOGY, 2005, 12 (05) : 456 - 464
[33] Cost Effectiveness of Controlled-Release Oxybutynin Compared with Immediate-Release Oxybutynin and Tolterodine in the Treatment of Overactive Bladder in the UK, France and Austria
Julian F. Guest
Dele Abegunde
Francis J. Ruiz
Clinical Drug Investigation, 2004, 24 : 305 - 321
[34] Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder
Varadharajan, S
Jumadilova, Z
Girase, P
Ollendorf, DA
AMERICAN JOURNAL OF MANAGED CARE, 2005, 11 (04): : S140 - S149
[35] Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment of overactive bladder in the UK, France and Austria
Guest, JF
Abegunde, D
Ruiz, FJ
CLINICAL DRUG INVESTIGATION, 2004, 24 (06) : 305 - 321
[36] COST EFFECTIVENESS OF SOLIFENACIN COMPARED WITH ORAL ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB) IN THE UK
Kelleher, C.
Aballea, S.
Maman, K.
Nazir, J.
Hakimi, Z.
Chambers, C.
Odeyemi, I. A.
VALUE IN HEALTH, 2014, 17 (07) : A469 - A469
[37] Re: Cost-Effectiveness of Percutaneous Tibial Nerve Stimulation Versus Extended Release Tolterodine for Overactive Bladder
Kaufman, Ronald P., Jr.
JOURNAL OF UROLOGY, 2012, 188 (06): : 2442 - 2442
[38] Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder
Kelleher, CJ
Reese, PR
Pleil, AM
Okano, GJ
AMERICAN JOURNAL OF MANAGED CARE, 2002, 8 (19): : S608 - S615
[39] Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder
Armstrong R.B.
Luber K.M.
Peters K.M.
International Urology and Nephrology, 2005, 37 (2) : 247 - 252
[40] The cost utility of solifenacin in the treatment of overactive bladder
Hakkaart, Leona
Verboom, Paul
Phillips, Richard
Al, Maiwenn J.
INTERNATIONAL UROLOGY AND NEPHROLOGY, 2009, 41 (02) : 293 - 298

← 1 2 3 4 5 →